The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry

Mon, 10th Oct 2022 12:10

(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.

The FTSE 100 index was down 22.82 points, or 0.3%, at 6,968.27. It had been 1.0% lower earlier on Monday.

The FTSE 250 was down 151.90 points, 0.9%, at 17,201.38. The AIM All-Share was down by 7.25 points, or 0.9%, at 802.97.

The Cboe UK 100 was down 0.3% at 696.07, the Cboe UK 250 fell 0.7% at 14,720.55, and the Cboe Small Companies was down 0.3% at 12,587.09.

In mainland Europe, the CAC 40 in Paris was down 0.4%, though the DAX 40 in Frankfurt was 0.4% higher.

Friday's nonfarm payrolls put paid to any hopes that the Federal Reserve will slow its pace of interest rate hikes. Equity market investors hoped US jobs growth would fall short of estimates and stay the Fed's hand.

Employment growth topped expectations, however, giving the Fed the impetus to add to its run of hefty rate hikes.

According to CME's FedWatch tool, which tracks interest rate probabilities, the market now thinks there is an 80% likelihood of a fourth successive 75 basis point rate hike early next month.

On Wednesday, minutes from the Fed's last meeting are released. On Thursday, the US consumer price index is out. The annual inflation rate is expected to slow to 8.1% in September from 8.3% in August. A higher-than-expected figure will likely spook markets further.

The next Federal Reserve interest rate decision is on November 2.

A few days before that, the UK government will take centre-stage again.

UK Chancellor Kwasi Kwarteng has bowed to pressure to bring forward the publication of his financial strategy and independent economic forecasts - to Halloween.

Completing another U-turn, Kwarteng agreed to set out his medium-term fiscal plan alongside Office for Budget Responsibility predictions on October 31.

The chancellor had been resisting setting out the details ahead of November 23 after he set out his multibillion-pound package of tax cuts to be paid for by borrowing.

The last big fiscal policy announcement, the mini-budget, spooked markets last month. It forced the Bank of England to intervene in bond markets.

The BoE on Monday doubled the size of that temporary bond-buying programme, but affirmed that it will end on Friday. The bank doubled the size of daily auctions to a maximum of GBP10 billion, from GBP5 billion before.

Following the announcement of the mini-budget last month, and the turmoil that ensued, the Bank of England decided to buy up long-dated UK government bonds, or gilts.

"With the pound remaining weak and government borrowing costs inching up again towards worrying levels, the UK government and the Bank of England have launched a two-pronged attempt to calm markets. Policymakers and politicians are clearly nervous about seeing a repeat of the mini-financial crisis unleashed following the presentation of the Truss administration's slash and spend plans, and fresh moves are being made to try to repair the damage," Hargreaves Lansdown analyst Susannah Streeter commented.

The dollar continued to rise following Friday's jobs report. The pound fell to USD1.1052 midday Monday in London from USD1.1130 late Friday. The euro declined to USD0.9698 from USD0.9779. Against the yen, the dollar was trading at JPY145.52, up from JPY145.15.

On the London Stock Exchange, DS Smith shares jumped 11%. It was the best large-cap performer heading into Monday afternoon.

The packaging firm lifted annual guidance, hailing "effective cost mitigation".

DS Smith expects adjusted operating profit of GBP400 million in the six months to October 31, up 45% from GBP276 million a year earlier.

For the full year, DS Smith's performance is "expected to be ahead of our previous expectations".

Peers Smurfit Kappa and Mondi were up 6.2% and 4.9% in a positive read across.

Moneysupermarket.com climbed 7.9%. RBC raised its recommendation for the price comparison site to 'outperform' from 'sector perform'.

Elsewhere in London, Evgen Pharma was the standout performer on AIM, jumping 65%.

It has signed a licencing deal for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.

The clinical stage drug development company said the deal with Swiss biotechnology company Stalicla may be worth as much as USD160.5 million.

According to the terms of the licencing deal, Evgen will receive USD500,000 upfront, followed by a further USD500,000 on completion of the fully financed phase one study.

Up to commercial launch, milestone payments are USD26.5 million, including USD5.0 million once the US Food & Drug Administration has granted investigational new drug status, anticipated in late 2023.

Total milestones of USD160.5 million are payable to Evgen in relation to the first neurodevelopmental disorder indication under the licence.

Evgen has a market capitalisation of just under GBP13 million.

Gold fell to USD1,678.84 an ounce midday Monday from USD1,702.27 at the time of the London equities close on Friday. Brent oil was quoted at USD97.33 a barrel, up from USD97.09 a barrel late Friday.

Stocks in New York were called lower on Monday, having suffered a sell-off on Friday. The Dow Jones Industrial Average was called down 0.1%, the S&P 500 down 0.3%, and the Nasdaq Composite down 0.4%.

The US third-quarter earnings season kicks off this week, with numbers from PepsiCo, BlackRock, JPMorgan Chase and Wells Fargo due.

"Earnings from PepsiCo on Wednesday, Walgreen Boots Alliance and Delta Airlines on Thursday, and then a slew of megabanks on Friday, kick-off the third-quarter results season in the USA and wobbling stock markets will be looking for reassurance that corporate profits are holding up," AJ Bell analyst Russ Mould commented.

"After recent stink-bombs from Nike, Seagate, Micron, AMD and Hasbro, to name but five, such reassurance may be hard to find and analysts' overall profit forecasts for the S&P 500 continue to fall."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 20:57

TRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
19 Mar 2024 19:47

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Feb 2024 15:59

Evgen Pharma finds evidence of SFX-01 activity in colon cancer models

(Alliance News) - Evgen Pharma PLC on Tuesday said it found further evidence of SFX-01 activity in models of colon cancer.

Read more
19 Feb 2024 11:45

Evgen Pharma shares up on studies into SFX-01 product progressing well

(Alliance News) - Evgen Pharma PLC on Monday said the studies into its SFX-01 product were progressing positively regarding its activity in Glioblastoma cells.

Read more
9 Feb 2024 18:53

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
9 Feb 2024 17:02

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

Read more
16 Jan 2024 18:59

IN BRIEF: Evgen partner raises USD17.4 million to support pipeline

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes that its partner in autism spectrum disorder and other neurodevelopmental disorders Stalicla SA has announced that it has raised USD17.4 million, inclusive of a credit facility. This is to to support programmes on STP1, Stalicla's first asset in ASD, and a further asset in substance use disorders together with a biosampling and patient identification study in ASD. Evgen says it continues to work with Stalicla on delivery of a milestone payment for SFX-01 (Stalicla's STP2). Evgen says both parties are engaged in analysis and interpretation of Evgen's recent Phase 1b healthy volunteer PK/PD study and the implications for a future phase 2 trial in ASD. Evgen says it will provide updates on the status of the programme in "due course" and has not anticipated any milestone payments from Stalicla in its financial forecasting.

Read more
22 Dec 2023 18:06

IN BRIEF: Evgen appoints Toni Hanninen as permanent CFO

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Appoints Toni Hanninen as permanent chief financial officer, adding that he will now join the board as a director. Hanninen was appointed as interim CFO in September, having previously worked at Faron Pharmaceuticals Ltd. His permanent appointment becomes effective from January 1. Evgen also confirms that non-executive director, Susan Clement-Davies, will be retiring from the board.

Read more
31 Oct 2023 14:38

TRADING UPDATES: Acuity RM wins contract; Georgia Capital ups earnings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday, and not separately reported by Alliance News:

Read more
26 Oct 2023 11:08

Evgen upbeat on start of glioblastoma research project

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Read more
19 Oct 2023 19:39

IN BRIEF: Evgen showcases importance of new enteric-coated formulation

Evgen Pharma PLC - Cheshire, England-based clinical stage drug developer - Highlights article published in respected industry publication the Medicine Maker, by its Chief Business Officer, Helen Kuhlman. The article, entitled the Sulforaphane Promise, focuses on the recent study of Evgen's new enteric-coated tablet formulation, and why enteric coatings are of particular importance for a stabilised complex such as SFX-01 that releases highly biologically active sulforaphane. The SFX-01 complex is vulnerable to breakdown in acid conditions and the enteric coat prevents acid attack in the stomach, releasing the drug in the ideal region - the small bowel. It also discusses the pharmacodynamic and pharmacokinetic data from the recent study, demonstrating the improvements of the tablet formulation over previous formulations of SFX-01.

Read more
5 Sep 2023 14:22

Evgen Pharma hires interim CFO from Faron, chair to retire this month

(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen.

Read more
15 Aug 2023 10:01

Evgen Pharma says trial shows new SFX-01 drug formulation is safe

(Alliance News) - Evgen Pharma PLC on Tuesday said final data from a trial of its SFX-01 therapy has shown a new formulation of the drug is safe.

Read more
2 Aug 2023 10:28

IN BRIEF: Evgen Pharma shares drop on ending of license agreement

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focused on developing sulforaphane-based medicines - Terminates the patent and know-how license agreement for its Sulforadex sulforaphane stabilisation technology with partner JuvLife Ltd. The exclusive rights will be returned in the final quarter of 2023. The already received upfront payment is non-refundable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.